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the perceived symptoms/disabilities was found in 94% (n=73), it
was partial in 3.8% (n=3) and no agreement occured in 2.2%
(n=2, both of whom needed support). The understanding was
rated very good in 98% and difficult in 2% (both elderly persons
>80 years). The formulation "my symptoms are ..." was preferred
by everybody compared to "which symptoms do you have". In
general the overall rating was good or very good for all persons,
although older people with comorbidities needed help.
Conclusions: The pationnaire accurately documentd the symp-
toms and disabilities present in people with active musculoscele-
tal disorders; it also revealed the range of symptoms. The agree-
ment between the answers in the questionaire and the perceived
symptoms/disabilities is high. Older people may need help to fill
it out, and this can markedly reduce the rate of misunderstanding
and misinterpretation. Most people can fill it out within 15 min-
utes. The pationnaire and the way to perform the assessment
from the standpoint of the persons/patients was welcomed by all
persons.
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Purpose: The aim of this study was to assess the subjective joint
pain, stiffness and function and the objective physical function of
lower extremities and the quadriceps femoris muscle thickness
and density in men with knee osteoarthritis (OA) and to compare
the results with those from age- and sex-matched controls.
Methods: Fifty-four men (aged 49-68 years) with unilateral or
bilateral hip OA and 53 age-matched randomly selected healthy
men were studied. According to the side of the highest radio-
graphic score (Kellgren-Lawrence grading scale) from the pa-
tients with clinical knee OA, 22.2% had grade 1, 27.8% grade
2, 35.2% grade 3, and 14.8% grade 4 OA. The range of mo-
tion (ROM) of the hip and knee joints was measured with go-
niometry and the Western Ontario and McMaster Universities
(WOMAC) OA index was determined. Musculoskeletal function
was assessed with a test battery. The isometric knee flexion
and extension strength (peak torque (Nm/kg))) was determined.
The thickness and density of quadriceps femoris muscle com-
partments were determined with muscle ultrasonography. Dif-
ferences between the radiographic OA subgroups and between
OA and control groups were determined by the Kruskal-Wallis
and general linear univariate model with analysis of covariances
(age, knee pain, BMI and height).
Results: In WOMAC OA index both stiffness and function, but not
pain were positively related (p<0.05) with radiographic severity of
OA. Most of the WOMAC items were significantly (p<0.05-0.001)
related to the performance tests. Knee flexion and hip inner
rotation were 8.4% and 19.4% lower (p<0.001) in the OA group
than in the controls, respectively. The controls were significantly
(p<0.001) better at ascending and descending stairs, performing
a 20-meter walk, 5-min walking and straight line walking (10 m)
tests and in repeated sit to stand and in the timed ’up and go’
tests compared to the knee OA patients. The knee isometric
flexion and extension strength was 11-18% lower (p<0.001) in
OA subjects than in controls. The thickness of rectus femoris,
vastus lateralis and vastus intermedius muscle compartments
were 7-14% lower (p<0.001) in the OA group than in the controls.
Also muscle density was significantly lower in rectus femoris and
vastus intermedius, but not in vastus lateralis compartment.
Conclusions: The physical function tests and WOMAC OA index
are useful measures in evaluation of functional severity of the
knee OA patients. The decrease of muscle size may contribute
to the decrease of musculoskeletal function in knee OA.
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Purpose: Increasingly pain management of osteoarthitis as car-
ried out by arthritis specialists needs to embrace techniques
used in pain management clinics. The authors have developed a
comprehensive approach to pain management entitled The Five
Pillars of Pain Management. This presentation demonstrates how
it can be applied to the treatment of osteoarthritis
Methods: The author developed the Five Pillars initially for
treatment of pelvic pain and also neuropathic pain. It came after
years of experience in pain management and explaining the
complexities to those not considered experts
Results: Pillar 1: Assessment of pain in the individual including
a risk assessment as described in "Universal Precautions in Pain
Management" (Gourlay et al 2005)
Pillar 2: Doing a history and physical exam and coming up with
an anatomical diagnosis and a pathological diagnosis and then
treat the underlying condition
Pillar 3: Making a pain diagnosis: acute or chronic; mild, mod-
erate, severe; cancer or non-cancer; nociceptive or neuropathic
and then going down the evidenced based path of treatment.
Pillar 4: Assessing and treating co-morbidities and complications
including anxiety, depression, sleep disturbence; addiction; and
sexual dysfunction
Pillar 5: Patient buy-in, practicing self management and appropi-
ate expectations
Conclusions: Pain management is often considered a ’swamp’
full of treacherous opiates, manipulative patients and many frus-
trations. The Five Pillars paradigm can be used to provide struc-
ture to a pain management program and allow the practitioner
to use a variety of techniques to improve the condition of the
patient.
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Purpose: Acute gout is a painful inflammatory disease affecting
an estimated 20 million people worldwide [1]. The NSAID in-
domethacin is often regarded as the gold standard for treatment
of acute flares of gout. Hypertension is reported as a frequent
condition in patients with acute gout, therefore managing BP
during treatment of acute gout needs to be considered.
In TARGET, lumiracoxib at a dose of 400 mg od has demon-
strated a superior BP profile compared to the NSAIDs ibuprofen
and naproxen after long-term treatment [2].
This study assessed whether the structurally distinct selective
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COX-2 inhibitor lumiracoxib (400 mg once daily [od]) has com-
parable efficacy to indomethacin (50 mg three times daily [tid])
for the treatment of acute flares of gout. Secondary analysis of
safety and tolerability included a specific, pre-defined comparison
of differences in blood pressure.
Methods: This was a 1-week, multicentre, randomized, double-
blind, double-dummy, active-controlled, parallel-group study of
lumiracoxib 400 mg od (n=118) vs indomethacin 50 mg tid
(n=117) (safety population) in patients with acute flares of gout.
The primary analysis was a test of non-inferiority in the per
protocol population of the mean change from baseline in pain
intensity in the study joint over Days 2-5.
The blood pressure profile was assessed by a pre-defined anal-
ysis of the mean change from baseline for systolic and diastolic
blood pressure.
Results: In the per protocol population, lumiracoxib 400 mg od
(n=112) was non-inferior to indomethacin 50 mg tid (n=110).
Least square mean (LSM) change from baseline in pain intensity
for lumiracoxib was 1.29 (1.47) vs 1.29 (1.50) over Days 2-5
(Days 2-7) treatment period for lumiracoxib and indomethacin,
respectively. Both drugs were also comparable in all secondary
efficacy assessments.
50% of the patients had a medical history of hypertension.
The table below shows the mean change from baseline in BP
for lumiracoxib vs indomethacin at study end, after 7 days of
treatment (safety population*).
Mean change/(SD) Lumiracoxib Indomethacin Two sided T-test
400 mg od n=114 50 mg tid n=116 p-value
Systolic blood
pressure (mmHg) -1.0 (9.74) 2.5 (10.68) 0.009
Diastolic blood
pressure (mmHg) -1.3 (6.06) 0.5 (6.57) 0.028
*Only patients with BP measurement at both baseline and study end were in-
cluded.
None of the patients in the lumiracoxib group showed a clinically
relevant increase in blood pressure (defined as change from
baseline of at least 25%), as compared to 1.7% of patients in the
indomethacin group.
Only 1.7% of the patients on lumiracoxib 400 mg od discontinued
study drug compared with 8.5% on indomethacin 50 mg tid. AEs
were reported in 10.2% of patients in the lumiracoxib group
compared with 22.2% of patients in the indomethacin group. Due
to suspected Good Clinical Practice non-compliance, a post-
hoc sensitivity analysis was performed after database closure
excluding a center containing 8 patients. The sensitivity analysis
revealed no substantial change of the study results, the only
exception was diastolic blood pressure (p=0.057).
Conclusions: Lumiracoxib 400 mg od is effective in the treat-
ment of acute gout with efficacy comparable to indomethacin
50 mg tid. In addition, even after short-term treatment, lumira-
coxib shows a favourable blood pressure profile as compared to
indomethacin, and with fewer AEs and discontinuations. Lumira-
coxib may thus provide an alternative effective treatment option
for acute gout.
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Purpose: To determine if there is an association between the
severity of ectopic bone formation after hip replacement surgery,
chronic hip pain and physical disability.
Methods: HIPAID was a double-blind randomised placebo-
controlled clinical trial conducted in 20 orthopaedic surgery cen-
tres in Australia and New Zealand.
902 patients undergoing elective primary or revision total hip re-
placement surgery were randomly allocated to 14 days treatment
with ibuprofen (1200mg daily) or matching placebo commenced
within 24 hours of surgery. Participants were required to have hip
radiographs, complete self-reported questionnaires measuring of
pain and physical function (WOMAC), report analgesia use and
undergo several physical performance measures (hip flexion, up
and go, 50ft walk time) six to twelve months after surgery.
Results: Hip radiographs were obtained from 798 (88%) par-
ticipants and scored for ectopic bone formation severity using
the Brooker grading (0-4). Among the 294 (37%) of HIPAID par-
ticipants with radiographic evidence of ectopic bone formation,
108 (37%) had at least moderate severity (Brooker grade 2, 3
or 4). Brooker grade 3 and 4 demonstrated increased pain and
function scores, compared with less severe grades of ectopic
bone formation; however this trend was not significant. There
were was also a trend in the physical performance measures,
but again this trend was not significant.
Ectopic bone formation and clinical outcomes
Brooker Grade Pain (0-10) Function (0-10)
mean (sd) mean (sd)
0 0.97 (1.47) 1.56 (1.57)
1 0.99 (1.49) 1.43 (1.57)
2 0.97 (1.57) 1.87 (1.79)
3 and 4 1.25 (1.85) 2.23 (1.95)
Conclusions: These data, from the largest-ever trial of pro-
phylaxis against ectopic bone formation, suggest that only a
small proportion of patients undergoing elective hip replacement
surgery will develop clinically relevant ectopic bone around the
new hip implant.
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Purpose: With the increased controversy associated with long-
term use of NSAIDs and COX-2 inhibitors, there is renewed
interest in the use of intraarticular (IA) injections, including
hyaluronans (HA), for the management of patients with knee os-
teoarthritis (OA). Non-animal stabilized hyaluronic acid (NASHA;
Durolane®) is administered as a single IA injection for OA of
the knee, and has an extended IA residence time (half-life: 4
